Who Buys Busulfan from India — 109 Importers Behind a $4.9M Market

The importation of Busulfan from India involves various buyer segments, each with distinct purchasing behaviors:

• Pharmaceutical Distributors: Entities like Accord Healthcare S.A.C. (Peru) and Tillomed Laboratories Ltd (United Kingdom) procure Busulfan in bulk to supply hospitals, clinics, and pharmacies. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as Fresenius Kabi Deutschland GmbH (Germany) and Mylan Institutional Inc GSO (United States) import Busulfan as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement is aligned with production schedules and market demand forecasts.

• Hospital Groups: Organizations like Eversana Life Sciences Services, LLC (United States) and Accord Farmaceutica Ltda (Brazil) import Busulfan directly for use in their healthcare facilities. Their purchasing behavior is driven by patient treatment needs and institutional formularies, often resulting in consistent, moderate-sized orders.

• Re-exporters: Entities such as Tillomed Malta Ltd (Malta) may act as intermediaries, importing Busulfan for redistribution to other markets. Their order patterns can be irregular, influenced by global demand fluctuations and trade agreements.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs of each buyer type.

The importation of Busulfan into the top five importing countries involves the following regulatory frameworks:

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Importers must hold a Wholesale Dealer's Licence (WDA(H)) and ensure that each batch is certified by a Qualified Person (QP) from an approved country.
• Estimated Timeline for Registration: The MHRA aims to process applications within 90 days, though this can vary based on the complexity of the application.
• Import Tariff/Duty for HS 30049049: Pharmaceutical products under this HS code are typically subject to a 0% import duty, aligning with the UK's commitment to facilitating access to essential medicines.

• Peru:
• Regulatory Authority: Dirección General de Medicamentos, Insumos y Drogas (DIGEMID).
• Import Registration Process: Importers must obtain a Sanitary Registration, which involves submitting technical documentation and samples for evaluation.
• Estimated Timeline for Registration: The process can take approximately 6 to 12 months, depending on the completeness of the application and any required inspections.
• Import Tariff/Duty for HS 30049049: Pharmaceutical imports are generally subject to a 6% import duty, though exemptions may apply for essential medicines.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure that the drug is FDA-approved and that the manufacturing facility is registered with the FDA.
• Estimated Timeline for Registration: Facility registration and drug listing can be completed within 60 days, but obtaining FDA approval for a new drug application can take several months to years.
• Import Tariff/Duty for HS 30049049: Most pharmaceutical products are duty-free under the Harmonized Tariff Schedule of the United States.

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Importers must hold a Manufacturer's Authorization and ensure that the product is authorized for the German market.
• Estimated Timeline for Registration: The authorization process can take 6 to 12 months, depending on the product and completeness of the application.
• Import Tariff/Duty for HS 30049049: As part of the European Union, Germany applies a 0% import duty on pharmaceutical products under this HS code.

• Malta:
• Regulatory Authority: Malta Medicines Authority (MMA).
• Import Registration Process: Importers must obtain a Wholesale Dealer Licence and ensure that the product is registered with the MMA.
• Estimated Timeline for Registration: The registration process typically takes 6 to 9 months.
• Import Tariff/Duty for HS 30049049: Malta, as an EU member state, applies a 0% import duty on pharmaceutical products under this HS code.

Navigating these regulatory landscapes requires thorough preparation and compliance to ensure successful market entry.

The demand for Busulfan is primarily driven by its critical role in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT), a treatment for various hematologic malignancies. The global incidence of such conditions has been rising, leading to increased HSCT procedures.

Government healthcare programs and the expansion of universal health coverage have also contributed to the demand. Many countries have included Busulfan in their national essential medicines lists, aligning with the World Health Organization's Essential Medicines List, which facilitates procurement through tender-based purchasing mechanisms. This approach ensures a consistent supply of Busulfan, particularly in low- and middle-income countries, thereby expanding market opportunities for exporters.

The presence of 109 buyers across 44 countries, as per TransData Nexus data, underscores the widespread and growing demand for Busulfan, presenting significant market potential for suppliers.

The importation of Busulfan from India involves various buyer segments, each with distinct purchasing behaviors:

• Pharmaceutical Distributors: Entities like Accord Healthcare S.A.C. (Peru) and Tillomed Laboratories Ltd (United Kingdom) procure Busulfan in bulk to supply hospitals, clinics, and pharmacies. Their purchasing patterns are characterized by large, regular orders to maintain a steady supply chain.

• Contract Manufacturers: Companies such as Fresenius Kabi Deutschland GmbH (Germany) and Mylan Institutional Inc GSO (United States) import Busulfan as an active pharmaceutical ingredient (API) for the production of finished dosage forms. Their procurement is aligned with production schedules and market demand forecasts.

• Hospital Groups: Organizations like Eversana Life Sciences Services, LLC (United States) and Accord Farmaceutica Ltda (Brazil) import Busulfan directly for use in their healthcare facilities. Their purchasing behavior is driven by patient treatment needs and institutional formularies, often resulting in consistent, moderate-sized orders.

• Re-exporters: Entities such as Tillomed Malta Ltd (Malta) may act as intermediaries, importing Busulfan for redistribution to other markets. Their order patterns can be irregular, influenced by global demand fluctuations and trade agreements.

Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs of each buyer type.

The importation of Busulfan into the top five importing countries involves the following regulatory frameworks:

• United Kingdom:
• Regulatory Authority: Medicines and Healthcare products Regulatory Agency (MHRA).
• Import Registration Process: Importers must hold a Wholesale Dealer's Licence (WDA(H)) and ensure that each batch is certified by a Qualified Person (QP) from an approved country.
• Estimated Timeline for Registration: The MHRA aims to process applications within 90 days, though this can vary based on the complexity of the application.
• Import Tariff/Duty for HS 30049049: Pharmaceutical products under this HS code are typically subject to a 0% import duty, aligning with the UK's commitment to facilitating access to essential medicines.

• Peru:
• Regulatory Authority: Dirección General de Medicamentos, Insumos y Drogas (DIGEMID).
• Import Registration Process: Importers must obtain a Sanitary Registration, which involves submitting technical documentation and samples for evaluation.
• Estimated Timeline for Registration: The process can take approximately 6 to 12 months, depending on the completeness of the application and any required inspections.
• Import Tariff/Duty for HS 30049049: Pharmaceutical imports are generally subject to a 6% import duty, though exemptions may apply for essential medicines.

• United States:
• Regulatory Authority: U.S. Food and Drug Administration (FDA).
• Import Registration Process: Importers must ensure that the drug is FDA-approved and that the manufacturing facility is registered with the FDA.
• Estimated Timeline for Registration: Facility registration and drug listing can be completed within 60 days, but obtaining FDA approval for a new drug application can take several months to years.
• Import Tariff/Duty for HS 30049049: Most pharmaceutical products are duty-free under the Harmonized Tariff Schedule of the United States.

• Germany:
• Regulatory Authority: Federal Institute for Drugs and Medical Devices (BfArM).
• Import Registration Process: Importers must hold a Manufacturer's Authorization and ensure that the product is authorized for the German market.
• Estimated Timeline for Registration: The authorization process can take 6 to 12 months, depending on the product and completeness of the application.
• Import Tariff/Duty for HS 30049049: As part of the European Union, Germany applies a 0% import duty on pharmaceutical products under this HS code.

• Malta:
• Regulatory Authority: Malta Medicines Authority (MMA).
• Import Registration Process: Importers must obtain a Wholesale Dealer Licence and ensure that the product is registered with the MMA.
• Estimated Timeline for Registration: The registration process typically takes 6 to 9 months.
• Import Tariff/Duty for HS 30049049: Malta, as an EU member state, applies a 0% import duty on pharmaceutical products under this HS code.

Navigating these regulatory landscapes requires thorough preparation and compliance to ensure successful market entry.

The demand for Busulfan is primarily driven by its critical role in conditioning regimens prior to hematopoietic stem cell transplantation (HSCT), a treatment for various hematologic malignancies. The global incidence of such conditions has been rising, leading to increased HSCT procedures.

Government healthcare programs and the expansion of universal health coverage have also contributed to the demand. Many countries have included Busulfan in their national essential medicines lists, aligning with the World Health Organization's Essential Medicines List, which facilitates procurement through tender-based purchasing mechanisms. This approach ensures a consistent supply of Busulfan, particularly in low- and middle-income countries, thereby expanding market opportunities for exporters.

The presence of 109 buyers across 44 countries, as per TransData Nexus data, underscores the widespread and growing demand for Busulfan, presenting significant market potential for suppliers.